sc 58125 has been researched along with transforming growth factor beta in 1 studies
| Studies (sc 58125) | Trials (sc 58125) | Recent Studies (post-2010) (sc 58125) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 93 | 0 | 15 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albo, D; Beauchamp, RD; Berger, DH; DuBois, RN; O'Mahony, CA; Shao, J; Sheng, H | 1 |
1 other study(ies) available for sc 58125 and transforming growth factor beta
| Article | Year |
|---|---|
Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions.
Topics: Animals; Cell Adhesion; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Extracellular Matrix; Fibrinolysin; Intestinal Mucosa; Isoenzymes; Neoplasm Invasiveness; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Transforming Growth Factor beta; Transforming Growth Factor beta1; Urokinase-Type Plasminogen Activator | 2003 |